Global Oncology Market Expected to Reach $748.17 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: Newsfilter
- Market Growth Potential: The global oncology market is projected to grow from $279.98 billion in 2026 to $748.17 billion by 2035, indicating strong growth potential driven by the rising demand for cancer treatments.
- Drug Revenue Forecast: Cancer drug revenues are expected to reach $335.2 billion by 2033, primarily fueled by the adoption of targeted therapies and immunotherapy, highlighting the urgent need for innovative treatment options in the market.
- Clinical Trial Progress: Oncolytics Biotech announced its focus on registrational programs in anal and colorectal cancer, with plans to meet with the FDA in mid-April 2026 to seek approval in this rare cancer indication, demonstrating its strategic positioning in clinical research.
- Leadership Changes: Oncolytics Biotech recently appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as Head of Biostatistics, further strengthening the company's leadership capabilities and competitive edge in the oncology treatment sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONCY
Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.060
Low
3.00
Averages
5.50
High
10.00
Current: 1.060
Low
3.00
Averages
5.50
High
10.00
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Shares Surge 12% on Promising Preclinical Data
- Clinical Trial Progress: Oncolytics is testing Pelareorep in combination with RAS-targeting drugs, demonstrating stronger anti-tumor effects in solid tumor models, with full results expected in fall or winter 2026, potentially offering new hope for future treatments in pancreatic and colorectal cancers.
- Strong Stock Rally: Oncolytics shares surged over 12% on Monday, gaining nearly 50% over the past six trading sessions, reflecting strong investor confidence in its experimental immunotherapy, with the stock approaching a key resistance level at $1.19.
- Expansion of Testing Plans: Based on preliminary findings, Oncolytics plans to expand testing into pancreatic ductal adenocarcinoma and colorectal cancer models, with future studies focusing on immune activation, durability of tumor response, and delaying treatment resistance, indicating the company's strategic emphasis on cancer treatment.
- Retail Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', amid high message volumes, indicating optimistic market expectations for Oncolytics' future performance, further fueling the stock's rise.
See More
Oncolytics Biotech Reveals Initial Preclinical Study Data
- Enhanced Anti-Tumor Activity: Oncolytics Biotech's preclinical study indicates that pelareorep combined with RAS inhibitors shows significantly greater anti-tumor activity than individual treatments, highlighting its potential in addressing hard-to-treat tumors.
- Follow-Up Research Plans: Based on initial findings, the company plans additional studies in pancreatic ductal adenocarcinoma and colorectal cancer models to evaluate the effects of combinations on immune activation, tumor response durability, and time-to-resistance, demonstrating a commitment to future treatment strategies.
- Market Demand Response: Given the extremely limited treatment options for pancreatic and colorectal cancers, Oncolytics' research may offer new hope for patients, particularly in RAS-mutated tumors, emphasizing pelareorep's potential as an immune-priming backbone.
- Future Data Release: The company expects to present full results from the initial studies in the fall or winter of 2026, further validating pelareorep's application in cancer treatment, which may attract increased investor interest.
See More
Oncolytics Biotech Presents New Data at ASCO Meeting
- Clinical Trial Data Presentation: Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the 2026 ASCO Annual Meeting, further validating the potential of its immunotherapy pelareorep in treating difficult cancers, likely attracting investor interest.
- Mechanism of Immune Response: The research indicates that pelareorep enhances immune responses against KRAS-mutant tumors by expanding pre-existing tumor-reactive immune cells rather than introducing new antigens, potentially providing new insights for future treatment strategies.
- Efficacy Metrics Improvement: In pancreatic cancer studies, the observed expansion of antiviral T cells correlated with reductions in tumor volume post-treatment, demonstrating pelareorep's ability to activate immune responses within the tumor microenvironment, which may improve patient outcomes.
- Strategic Partnerships and Development: Oncolytics is actively pursuing strategic partnerships to accelerate the development of pelareorep, particularly in colorectal and pancreatic cancers where the FDA has granted Fast Track designation, indicating the company's focus on market opportunities.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep
- Clinical Trial Alignment: Oncolytics Biotech has reached an agreement with the FDA on the design of a pivotal clinical study to support the approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal, indicating the company's proactive progress in developing new therapies.
- Significant Patient Need: Over 10,000 patients are affected by SCAC annually in the U.S., and with no FDA-approved treatment options available after first-line chemotherapy or checkpoint inhibitor therapy, the market potential for pelareorep is substantial.
- Enhanced Efficacy: In a recent study, the combination of pelareorep with a checkpoint inhibitor achieved a median duration of response of 15.5 months compared to 9.5 months with the current standard of care, demonstrating its effectiveness in treating SCAC.
- Strategic Partnership Opportunities: Oncolytics plans to incorporate FDA feedback into the final protocol, with a randomized controlled trial expected to apply for both accelerated and full approval at different points in time, further advancing its strategic development in cancer immunotherapy.
See More
ONCOLYTICS BIOTECH INC - CONFIRMS FDA ALIGNMENT FOR KEY ANAL CANCER TRIAL - SEC FILING
Announcement of Collaboration: Oncolytics Biotech Inc. has announced a strategic alignment with the FDA regarding a pivotal cancer study.
Focus on Cancer Research: The collaboration aims to enhance the development and evaluation of innovative cancer therapies.
See More
Oncolytics Biotech Shares Surge 12% on Promising Preclinical Data
- Clinical Trial Progress: Oncolytics is testing Pelareorep in combination with RAS-targeting drugs, demonstrating stronger anti-tumor effects in solid tumor models, with full results expected in fall or winter 2026, potentially offering new hope for future treatments in pancreatic and colorectal cancers.
- Strong Stock Rally: Oncolytics shares surged over 12% on Monday, gaining nearly 50% over the past six trading sessions, reflecting strong investor confidence in its experimental immunotherapy, with the stock approaching a key resistance level at $1.19.
- Expansion of Testing Plans: Based on preliminary findings, Oncolytics plans to expand testing into pancreatic ductal adenocarcinoma and colorectal cancer models, with future studies focusing on immune activation, durability of tumor response, and delaying treatment resistance, indicating the company's strategic emphasis on cancer treatment.
- Retail Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', amid high message volumes, indicating optimistic market expectations for Oncolytics' future performance, further fueling the stock's rise.
See More
Oncolytics Biotech Reveals Initial Preclinical Study Data
- Enhanced Anti-Tumor Activity: Oncolytics Biotech's preclinical study indicates that pelareorep combined with RAS inhibitors shows significantly greater anti-tumor activity than individual treatments, highlighting its potential in addressing hard-to-treat tumors.
- Follow-Up Research Plans: Based on initial findings, the company plans additional studies in pancreatic ductal adenocarcinoma and colorectal cancer models to evaluate the effects of combinations on immune activation, tumor response durability, and time-to-resistance, demonstrating a commitment to future treatment strategies.
- Market Demand Response: Given the extremely limited treatment options for pancreatic and colorectal cancers, Oncolytics' research may offer new hope for patients, particularly in RAS-mutated tumors, emphasizing pelareorep's potential as an immune-priming backbone.
- Future Data Release: The company expects to present full results from the initial studies in the fall or winter of 2026, further validating pelareorep's application in cancer treatment, which may attract increased investor interest.
See More
Oncolytics Biotech Presents New Data at ASCO Meeting
- Clinical Trial Data Presentation: Oncolytics Biotech will present translational data from the GOBLET and AWARE-1 trials at the 2026 ASCO Annual Meeting, further validating the potential of its immunotherapy pelareorep in treating difficult cancers, likely attracting investor interest.
- Mechanism of Immune Response: The research indicates that pelareorep enhances immune responses against KRAS-mutant tumors by expanding pre-existing tumor-reactive immune cells rather than introducing new antigens, potentially providing new insights for future treatment strategies.
- Efficacy Metrics Improvement: In pancreatic cancer studies, the observed expansion of antiviral T cells correlated with reductions in tumor volume post-treatment, demonstrating pelareorep's ability to activate immune responses within the tumor microenvironment, which may improve patient outcomes.
- Strategic Partnerships and Development: Oncolytics is actively pursuing strategic partnerships to accelerate the development of pelareorep, particularly in colorectal and pancreatic cancers where the FDA has granted Fast Track designation, indicating the company's focus on market opportunities.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep
- Clinical Trial Alignment: Oncolytics Biotech has reached an agreement with the FDA on the design of a pivotal clinical study to support the approval of pelareorep for patients with unresectable metastatic squamous cell carcinoma of the anal canal, indicating the company's proactive progress in developing new therapies.
- Significant Patient Need: Over 10,000 patients are affected by SCAC annually in the U.S., and with no FDA-approved treatment options available after first-line chemotherapy or checkpoint inhibitor therapy, the market potential for pelareorep is substantial.
- Enhanced Efficacy: In a recent study, the combination of pelareorep with a checkpoint inhibitor achieved a median duration of response of 15.5 months compared to 9.5 months with the current standard of care, demonstrating its effectiveness in treating SCAC.
- Strategic Partnership Opportunities: Oncolytics plans to incorporate FDA feedback into the final protocol, with a randomized controlled trial expected to apply for both accelerated and full approval at different points in time, further advancing its strategic development in cancer immunotherapy.
See More
ONCOLYTICS BIOTECH INC - CONFIRMS FDA ALIGNMENT FOR KEY ANAL CANCER TRIAL - SEC FILING
Announcement of Collaboration: Oncolytics Biotech Inc. has announced a strategic alignment with the FDA regarding a pivotal cancer study.
Focus on Cancer Research: The collaboration aims to enhance the development and evaluation of innovative cancer therapies.
See More
